Dynamic analysis of the immunological response of Balb/c mice with experimental breast cancer submitted to immunotherapy treatment of dendritic cell/ Análise dinâmica da resposta imunológica de camundongos Balb/c com câncer de mama experimental submetido a imunoterapia de células dendríticas

Marcia Antoniazi Michelin, Eddie Fernando Cândido Murta, Saulo Fernando Moreira da Silva

Abstract


INTRODUCTION: Cancer is a complex disease because it is capable of inhibiting the immune response through tumor escape mechanisms. OBJECTIVE: analyze the dynamics of the immune system during cancer treatment with dendritic cell immunotherapy. We evaluated the presence of tumor infiltrate of CD8 T lymphocytes, transcription factors of CD4 T lymphocytes in the spleen of these animals, the development of tumor volume and the behavior of coestimulatory molecules.  METHODS: 70 female Balb/c mice were divided into experimental and control groups, they were evaluated on the 7th e 14th days after tumor challenge and dendritic cell immunotherapy. RESULTS: Molecules such as T-bet, showed an increased expression in treated tumor group. Our results also demonstrated the higher MFI of CD8 + T lymphocytes infiltrate in the treated groups. Thus, there is a greater MFI of protumoral co-stimulatory molecules such as CTLA4 in the untreated groups. CONCLUSION: the immune system is able to modulate an immune response against tumor within 14 days if the organism is being treated with dendritic cell immunotherapy.


Keywords


dendritic cell immunotherapy, breast cancer, active immunotherapy.

Full Text:

PDF

References


Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol [Internet]. 2020;8:807–21. Available from: http://dx.doi.org/10.1038/s41423-020-0488-6

Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T, et al. The promise of Immuno-oncology: Implications for defining the value of cancer treatment. J Immunother Cancer. 2019;7:1–11.

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175–96.

Lee JY, Lee HT, Shin W, Chae J, Choi J, Kim SH, et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun [Internet]. 2016;7:1–10. Available from: http://dx.doi.org/10.1038/ncomms13354

Perica K, Varela JC, Oelke M, Schneck J. Adoptive T Cell Immunotherapy For Cancer. Rambam Maimonides Med J. 2015;6:4.

Calmeiro J, Carrascal MA, Tavares AR, Ferreira DA, Gomes C, Falcão A, et al. Dendritic cell vaccines for cancer immunotherapy: The role of human conventional type 1 dendritic cells. Pharmaceutics. 2020;12:1–20.

Ribatti D. The concept of immune surveillance against tumors. The first theories. Oncotarget. 2017;8:7175–80.

O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151–67.

Swann JB, Smyth MJ. Review series Immune surveillance of tumors. J Clin Invest. 2007;117:1137–46.

Comber JD, Philip R. MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Ther Adv Vaccines. 2014;2:77–89.

Andersen MH, Schrama D, Thor Straten P, Becker JC. Cytotoxic T cells. J Invest Dermatol [Internet]. 2006;126:32–41. Available from: http://dx.doi.org/10.1038/sj.jid.5700001

Goadsby PJ, Kurth T, Pressman A. Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol. 2016;35:1252–60.

Landskron G, De La Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014.

Messerschmidt JL, Prendergast GC, Messerschmidt GL. How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. Oncologist. 2016;21:233–43.

Butterfield LH. Dendritic cells in cancer immunotherapy clinical trials: Are we making progress? Front Immunol. 2013;4:3–9.

Geijtenbeek TBH, Gringhuis SI. Dendritic Cell Immunotherapy, the Next Step in Cancer Treatment. Multidiscip Cancer Investig. 2017;1:465–79.

Breckpot K, Escors D. Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification. Endocrine, Metab Immune Disord - Drug Targets. 2012;9:328–43.

Shibuya TY, Nugyen N, McLaren CE, Li KT, Wei WZ, Kim S, et al. Clinical significance of poor CD3 response in head and neck cancer. Clin Cancer Res. 2002;8:745–51.

Tian CT, Lu SX, Fan QX, Zhang WJ, Jiao SC, Zhao X, et al. Prognostic significance of tumor-infiltrating CD8+ or CD3+ T lymphocytes and interleukin-2 expression in radically resected non-small cell lung cancer. Chin Med J (Engl). 2015;128:105–10.

Al-Saleh K, El-Aziz NA, Ali A, Abozeed W, El-Warith AA, Ibraheem A, et al. Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. Oncol Lett. 2017;14:337–44.

Shimizu S, Hiratsuka H, Koike K, Tsuchihashi K, Sonoda T, Ogi K, et al. Tumor-infiltrating CD8+ T-cell density is an independent prognostic marker for oral squamous cell carcinoma. Cancer Med. 2019;8:80–93.

Zhao Y, Yang W, Huang Y, Cui R, Li X, Li B. Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy. Cell Physiol Biochem. 2018;47:721–34.

Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol. 2015;4:1–6.

Sckisel GD, Mirsoian A, Bouchlaka MN, Tietze JK, Chen M, Blazar BR, et al. Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. Cancer Immunol Immunother. 2015;64:1541–52.

Santoni G, Amantini C, Morelli MB, Tomassoni D, Santoni M, Marinelli O, et al. High CTLA-4 expression correlates with poor prognosis in thymoma patients. Oncotarget. 2018;9:16665–77.

Neeha Zaidi, Sergio A. Quezada, Janelle M.Y. Kuroiwa1, Li Zhang, Elizabeth M. Jaffee , Ralph M. Steinman and BW. Anti–CTLA-4 synergizes with dendritic cell–targeted vaccine to promote IL-3–dependent CD4+ effector T cell infiltration into murine pancreatic tumors. 2019;1445:62–73.

Esmaily M, Masjedi A, Hallaj S, Nabi Afjadi M, Malakotikhah F, Ghani S, et al. Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine. J Control Release [Internet]. 2020;326:63–74. Available from: https://doi.org/10.1016/j.jconrel.2020.06.017

Mondino A, Khoruts A, Jenkins MK. The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci U S A. 1996;93:2245–52.

Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019;234:8509–21.

Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T, et al. CD8 T cell score as a prognostic biomarker for triple negative breast cancer. Int J Mol Sci. 2020;21:1–16.

Kim SH, Go S Il, Song DH, Park SW, Kim HR, Jang I, et al. Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. Br J Cancer. 2019;120:547–54.

Mori H, Kubo M, Kai M, Yamada M, Kurata K, Kawaji H, et al. T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer. Breast Cancer Res Treat [Internet]. 2019;176:569–77. Available from: https://doi.org/10.1007/s10549-019-05256-2

Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH, et al. A Novel Transcription Factor , T-bet , Directs Th1 Lineage Commitment. 2000;100:655–69.

Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γin tumor progression and regression: A review. Biomark Res. 2020;8:1–16.

Ylikoski E, Lund R, Kyläniemi M, Filén S, Kilpeläinen M, Savolainen J, et al. IL-12 up-regulates T-bet independently of IFN-γ in human CD4+ T cells. Eur J Immunol. 2005;35:3297–306.

Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. J Immunol. 2003;198:986–92.

Chen Z, Lin F, Gao Y, Li Z, Zhang J, Xing Y, et al. FOXP3 and RORγt: Transcriptional regulation of Treg and Th17. Int Immunopharmacol. 2011;11:536–42.

Dahal LN. The dichotomy of T helper 17 cells in cancer. Nat Rev Immunol [Internet]. 2017;17:592. Available from: http://dx.doi.org/10.1038/nri.2017.93

Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci. 2019;110:2080–9.




DOI: https://doi.org/10.34117/bjdv7n7-101

Refbacks

  • There are currently no refbacks.